Document is current
Any future updates will be listed below
-
Authors
Christiansen, Katrine https://orcid.org/0009-0002-4548-9703
Nørgaard, Sidse K.
Nørgaard, Kirsten
Clausen, Tine D.
Damm, Peter
Mathiesen, Elisabeth R.
Ringholm, Lene https://orcid.org/0000-0003-2971-8043
-
Funding
Funding for this research was provided by:
National Hospital
- License Information
-
More Information
Article History
Received: 19 February 2025
Accepted: 27 June 2025
First Online: 4 August 2025
Declarations
:
: In September 2024 S.K.N. commenced a position at Novo Nordisk. K.N. has received funding from Novo Nordisk for an investigator-initiated trial (grant number U1111-1209-6358) with faster acting insulin aspart in insulin pump-treated adults with diabetes, is an advisory board member, for which an honorarium was given to her institution Steno Diabetes Center Copenhagen and owns stocks in Novo Nordisk. P.D. has participated in clinical studies on the use of insulin in pregnant women with preexisting diabetes in collaboration with Novo Nordisk, but no personal honorarium was involved. E.R.M. has contracts with Novo Nordisk for the Expect trial and the Evolve trial investigating newer insulin analogs and insulin pump treatment in pregnant women with diabetes, has received fees from Novo Nordisk for lectures, received financial support from Novo Nordisk for traveling to one international scientific meeting in the field of diabetes, and is participating on an advisory board for Novo Nordisk. L.R. has a contract with Novo Nordisk for the CopenFast trial investigating newer insulin analogs in pregnant women with diabetes. K.C. and T.D. declare no conflict of interests.
